

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)

Status: Completed

Eligibility Criteria

Age: 18 Years and over

This study is NOT accepting healthy volunteers

Conditions & Interventions

Conditions:

Diabetes & Endocrine, Heart & Vascular, Type 2 Diabetes Mellitus

Keywords:

Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glucose Metabolism Disorders, Heart Disease, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Hypoglycemic Agents, Incretins, Metabolic Diseases, Physiological Effects of Drugs, Tirzepatide, Type 2 Diabetes

More Information

Description: Study I8F-MC-GPGN (GPGN), also known as SURPASS-CVOT, is a Phase 3, event-driven, multicenter, international, randomized, double-blind, active comparator, parallel-group study. This study will assess the effect of QW tirzepatide (up to 15 mg) versus dulaglutide (1.5 mg) on CV outcomes when added to the standard of care in patients with T2DM with established cardiovascular disease and elevated risk for MACE.

Contact(s): Ndip Takang - natakang@healtheast.org

Principal Investigator: Les Forgosh

Phase: Phase III

IRB Number: STUDY00009070

System ID: NCT04255433

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.